← All trials
NCT02728180
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2016
- Primary completion
- May 1, 2017
- Completion date
- May 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 720
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Peking UniversityLead sponsor
- Peking UniversityOverall official - principal investigator
- Peking UniversityReponsible party - principal investigator
- Guangdong Provincial Hospital of Traditional Chinese MedicineCollaborator
- Jilin UniversityCollaborator
- Shaanxi Provincial People's HospitalCollaborator
- Capital Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Deyang People's HospitalCollaborator
- Hunan Academy of Chinese MedicineCollaborator
- Jiangmen Wuyi Hospital of Traditional Chinese MedicineCollaborator
- Mianyang Central HospitalCollaborator
- Tianshui Hospital of Traditional Chinese MedicineCollaborator
- Wuxi Hospital of Traditional Chinese MedicineCollaborator
- Zhejiang Chinese Medical UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Jiangxi Provincial People's HospitalCollaborator
- Nanjing UniversityCollaborator
- Shandong UniversityCollaborator
- Xiamen UniversityCollaborator
- Zibo City First HospitalCollaborator
- Hebei UniversityCollaborator
- Shaanxi University of Chinese MedicineCollaborator
- Guangzhou UniversityCollaborator
- Chengdu University of Traditional Chinese MedicinesCollaborator
- Henan Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.